Histone deacetylase inhibitor and hypomethylating agent effect on diffuse large B-cell lymphoma cell lines
Summary:
Analysis of three large B-cell lymphoma cell lines treated with the histone deacetylase inhibitor panobinostat, hypomethylating agent decitabine, or both for 48hrs. Panobinostat synergizes with decitabine in DLBCL cells. Results provide insight into the molecular basis for this synergistic effect.
Kalac M, Scotto L, Marchi E, Amengual J et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 2011 Nov 17;118(20):5506-16. PMID: 21772049
